Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-small Cell Lung Cancer (NSCLC) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Evidera

London, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients

Aged ≥18 years at the time of enrollment in the study
Resident of the US, Germany, or Japan
Able to read, speak, and understand English, German or Japanese
Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)

Physicians

Resident of the US, Germany, or Japan
Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
Treated at least three new patients with resectable NSCLC in the past year

Exclusion criteria

Patients

Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
Being diagnosed with another malignancy alongside NSCLC
Not willing to be audio-recorded during the interview

Physicians

Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
Not willing to be audio-recorded during the interview

Treatment and study plan

Approved Non-small Cell Lung Cancer (NSCLC) therapies

Drug

As prescribed by treating physician

Primary outcomes

Responses to qualitative interview questions

Time frame: Day 1

Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.
Patient sociodemographic

Time frame: Day 1
Patient clinical characteristics

Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Bristol-Myers Squibb

Industry

Registry information

Official study title

Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Jun 7, 2024
Registry last updated: Aug 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed